Author(s): Handelsman Y, Jellinger PS
Type 2 diabetes mellitus (T2DM) is characterized by progressively worsening hyperglycemia that leads to microvascular and macrovascular complications. Optimal management of T2DM aims to simultaneously control hyperglycemia, hypertension, and dyslipidemia to reduce the overall risk. However, a large proportion of patients in clinical practice do not reach treatment targets. Some of the obstacles to achieving treatment targets include high medication costs, costs associated with health insurance, poor patient adherence to medication, patient fear of potential adverse effects, improper patient education, and failure by health care providers to appropriately initiate or intensify therapy (clinical inertia). Possible causes of clinical inertia include the influence exerted on physicians by reluctant patients and the influence of media-driven attention and the negative spin of clinical trial results on physicians' prescribing behavior and on patients' attitudes towards treatment. This negative publicity can be disproportionate to the overall body of scientific evidence and may, therefore, prove to be unfounded in the long-term. There is clear evidence of the benefits of the effective management of T2DM to achieve goals. Overcoming the obstacles to achieving treatment targets may include use of strategies such as early intensive treatment and combination therapy with drugs with complementary mechanisms of action.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/21806772
Author(s): Selby JV, Ray GT, Zhang D, Colby CJ
Author(s): Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, et al.
Author(s): Cutajar J
Author(s): Costa J, Borges M, David C, Vaz Carneiro A
Author(s): IDF Clinical Guidelines Task Force
Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.
Author(s): Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J
Author(s): The Mount Hood 4 Modeling Group
Author(s): Clark CM Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG
Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.
Author(s): Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al.
Author(s): Carr MC, Brunzell JD
Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.
Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group
Author(s): Serrano Rios M
Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.
Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR
Author(s): Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al.
Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.
Author(s): Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R
Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.
Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.
Author(s): Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al.
Author(s): Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, et al.
Author(s): Anderson JW, Kendall CW, Jenkins DJ
Author(s): Metascreen Writing Committee, Bonadonna R, Cucinotta D, Fedele D, Riccardi G, et al.
Author(s): Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross GL
Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.